Exciting news.
I can't wait to see the look on Jon's face at 10:30am.
Jon has mentioned that 2591 is expected to be like but better than Trofinetide with less side effects. Well, we are hearing news about Daybue that its benefits for the person with Rhett continue to improve as they continue to take Daybue over time. So I am wondering that someone with PMS may obtain similar improving benefits from 2591 over time. So could the others areas that were not considered significant in the Phase 2 trial hopefully may come to life and improve the longer the person takes 2591? It would be good to hear Jon's view in this.
Enjoy today all.
Yahoo
Ann: P2 trial shows significant improvements in Phelan-McDermid, page-50
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.26 |
Change
-0.280(2.23%) |
Mkt cap ! $1.525B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $6.952M | 570.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 231 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.32 | 1979 | 2 |
View Market Depth
| Last trade - 16.13pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |